70 related articles for article (PubMed ID: 37711168)
1. Apoptosis-modulatory miR-361-3p as a novel treatment target in endocrine-responsive and endocrine-resistant breast cancer.
Zamarbide Losada JN; Sulpice E; Combe S; Almeida GS; Leach DA; Choo J; Protopapa L; Hamilton MP; McGuire S; Gidrol X; Bevan CL; Fletcher CE
J Endocrinol; 2023 Mar; 256(3):. PubMed ID: 36622663
[TBL] [Abstract][Full Text] [Related]
2. The estrogen/miR-338-3p/ADAM17 axis enhances the viability of breast cancer cells via suppressing NK cell's function.
Shi Y; Pan J; Hang C; Tan L; Hu L; Yan Z; Zhu J
Environ Toxicol; 2023 Jul; 38(7):1618-1627. PubMed ID: 37052432
[TBL] [Abstract][Full Text] [Related]
3. Serine synthesis influences tamoxifen response in ER+ human breast carcinoma.
Metcalf S; Petri BJ; Kruer T; Green B; Dougherty S; Wittliff JL; Klinge CM; Clem BF
Endocr Relat Cancer; 2021 Jan; 28(1):27-37. PubMed ID: 33112838
[TBL] [Abstract][Full Text] [Related]
4. Association between circHIPK3/miR-378a-3p/HDAC4 axis and osteoporotic fractures: A comprehensive investigation.
Wang L; Sheng Z; Yao T
J Orthop Surg (Hong Kong); 2023; 31(3):10225536231219637. PubMed ID: 38031987
[TBL] [Abstract][Full Text] [Related]
5. USP46 enhances tamoxifen resistance in breast cancer cells by stabilizing PTBP1 to facilitate glycolysis.
Gao S; Wang Y; Xu Y; Liu L; Liu S
Biochim Biophys Acta Mol Basis Dis; 2024 Mar; 1870(3):167011. PubMed ID: 38176460
[TBL] [Abstract][Full Text] [Related]
6. Pterostilbene-isothiocyanate reduces miR-21 level by impeding Dicer-mediated processing of pre-miR-21 in 5-fluorouracil and tamoxifen-resistant human breast cancer cell lines.
Kumar V; Haldar S; Saini S; Ghosh S; Dhankhar P; Roy P
3 Biotech; 2023 Jun; 13(6):193. PubMed ID: 37205177
[TBL] [Abstract][Full Text] [Related]
7. An indirect role for oncomir-519b in the expression of truncated neurokinin-1 in breast cancer cells.
Navarro P; Ramkissoon SH; Shah S; Park JM; Murthy RG; Patel SA; Greco SJ; Rameshwar P
Exp Cell Res; 2012 Dec; 318(20):2604-15. PubMed ID: 22981979
[TBL] [Abstract][Full Text] [Related]
8. Novel polymorphism rs12402181 in the mature sequence of hsa-miR-3117-3p has a protective effect against breast cancer development by affecting miRNA processing and function.
Mirabbasi R; Ebrahimi SO; Tavakoli F; Reiisi S
3 Biotech; 2023 Nov; 13(11):349. PubMed ID: 37780804
[TBL] [Abstract][Full Text] [Related]
9. Tooth loss in breast cancer patients: A comparison between tamoxifen-treated and non-treated patients.
Julca-Baltazar JJ; Asmat-Abanto AS; Pantoja-Lázaro AR; Gorritti-Rubio AP; Minchón-Medina CA
Med Oral Patol Oral Cir Bucal; 2024 May; ():. PubMed ID: 38794935
[TBL] [Abstract][Full Text] [Related]
10. Knockdown circTRIM28 enhances tamoxifen sensitivity via the miR-409-3p/HMGA2 axis in breast cancer.
Yang S; Zou C; Li Y; Yang X; Liu W; Zhang G; Lu N
Reprod Biol Endocrinol; 2022 Sep; 20(1):146. PubMed ID: 36180890
[TBL] [Abstract][Full Text] [Related]
11. Overexpression miR-24-3p repressed Bim expression to confer tamoxifen resistance in breast cancer.
Han X; Li Q; Liu C; Wang C; Li Y
J Cell Biochem; 2019 Aug; 120(8):12966-12976. PubMed ID: 31001849
[TBL] [Abstract][Full Text] [Related]
12. The role of mitochondrial/metabolic axis in development of tamoxifen resistance in breast cancer.
Azzam HN; El-Derany MO; Wahdan SA; Faheim RM; Helal GK; El-Demerdash E
Hum Cell; 2023 Nov; 36(6):1877-1886. PubMed ID: 37646973
[TBL] [Abstract][Full Text] [Related]
13. Candidate Oligo Therapeutic Target, miR-330-3p, Induces Tamoxifen Resistance in Estrogen Receptor-Positive Breast Cancer Cells via HDAC4.
Zhang M; Wang M; Jiang Z; Fu Z; Ma J; Gao S
Breast J; 2023; 2023():2875972. PubMed ID: 37711168
[TBL] [Abstract][Full Text] [Related]
14. Functional role of miR-10b in tamoxifen resistance of ER-positive breast cancer cells through down-regulation of HDAC4.
Ahmad A; Ginnebaugh KR; Yin S; Bollig-Fischer A; Reddy KB; Sarkar FH
BMC Cancer; 2015 Jul; 15():540. PubMed ID: 26206152
[TBL] [Abstract][Full Text] [Related]
15. miR-449a Suppresses Tamoxifen Resistance in Human Breast Cancer Cells by Targeting ADAM22.
Li J; Lu M; Jin J; Lu X; Xu T; Jin S
Cell Physiol Biochem; 2018; 50(1):136-149. PubMed ID: 30278449
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
